Abstract
Exposure therapy has recently been gaining increasing attention for the treatment of a range of anxiety disorders. Recently, strategies to facilitate extinction of fear memory have attracted increasing attention for enhancing the effectiveness of exposure therapy. There is a strong clinical need for an anxiolytic drug that 1)does have potent anxiolytic effect, 2)does not impair recognition memory, 3)does not impair (or even facilitates) extinction learning and 4)attenuates reconsolidation of fear memory. A drug with these features would enhance exposure therapy without the undesired side effects reported for benzodiazepines, SSRIs and D-cycloserine.
